|[January 31, 2014]
AGTC Appoints Larry Bullock as Chief Financial Officer
GAINESVILLE, Fla. --(Business Wire)--
AGTC, a clinical stage biotechnology company developing adeno-associated
virus (AAV)-based gene therapies for the treatment of rare eye diseases,
today announced the appointment of Larry Bullock to the position of
Chief Financial Officer.
Mr. Bullock has more than 30 years of financial executive management
experience, including over two decades as a chief financial officer in
the biotechnology industry. In his previous positions as Chief Financial
Officer, he has successfully navigated the IPO process three times,
building a body of expertise in all aspects of the financial management
of a biotechnology company, including private and public company
financing, SEC (News - Alert) reporting, and establishing collaborations and licensing
agreements between biotechnology and pharmaceutical companies. Mr.
Bullock also has experience in marketing-based financial analysis,
operations management, and sales.
"Larry brings a strong track record of success helping growing
biotechnology companies effectively manage their assets," said Sue
Washer, President and CEO of AGTC. "As we continue advancing our
pipeline of gne-based therapies for the treatment of rare eye and lung
diseases, we are certain that Larry's ability to provide us with
financial leadership will be a valuable asset to us. I am delighted to
welcome Larry to the AGTC management team."
Most recently, Mr. Bullock was Chief Financial Officer and Corporate
Secretary at BioMimetic Therapeutics, Inc., which he successfully took
public and after nearly a decade with the company, was instrumental in
the process of selling it to Wright Medical in 2013. From 1996 to 2003,
he was with Ribozyme Pharmaceuticals, where he served as Chief Financial
Officer and also led the company's IPO process. Previously, Mr. Bullock
served as Chief Financial Officer at La Jolla Pharmaceuticals, Inc.,
which he also took public, and as Chief Financial Officer and a Founding
Partner of Natural Products, Inc. Mr. Bullock's prior experience
includes seven years with Warner Lambert, where he held positions of
increasing responsibility in cost accounting, international finance and
sales. He holds a Bachelor of Arts degree in Business Administration
from Indiana University (News - Alert) and a Master of Business Administration in
Finance and Marketing from the University of Utah.
AGTC is a privately held, clinical-stage biotechnology company creating
first-in-class treatments for rare eye diseases caused by mutated genes.
The company currently has five programs in development from pre-clinical
through Phase 2, with lead orphan ophthalmology programs in
Achromatopsia (ACHM) and X-Linked Retinoschisis (XLRS). AGTC's gene
therapy platform uses a safe and effective delivery system based on the
adeno-associated virus (AAV). A single injection has the potential to
provide long-lasting treatment and once FDA approval is obtained, to
lead to a better quality of life for patients worldwide. AGTC is
headquartered in Alachua, FL. For more information, please visit www.agtc.com.
[ InfoTech Spotlight's Homepage ]